河北常山生化药业股份有限公司 证券代码：300255 证券简称：常山药业 公告编号：2025-37 关于为公司提供担保的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、担保情况概述 河北常山生化药业股份有限公司（以下简称"公司"、"母公司"）于 2025 年 5 月 19 日召开的 2024 年度股东大会审议并通过《关于提供担保额度预计的议 案》，同意全资子公司常山生化药业（江苏）有限公司（以下简称"江苏子公司"） 为母公司借款融资提供不超过 10.4 亿元的担保额度，上述额度期限自股东大会 审议通过之日起至 2025 年度股东大会之日。具体内容详见公司刊登于巨潮资讯 网的《关于提供担保额度预计的公告》（公告编号：2025-14）。 二、担保进展 2025 年 9 月 3 日，江苏子公司与中国建设银行股份有限公司正定支行（以 下简称"建设银行"）签订了《本金最高额保证合同》，江苏子公司为公司与建设 银行签订的借款等融资合同总额度不超过人民币 6 亿元整的本金及利息提供连 带责任保证。 本次担保事项在已经审议的担保额度范围内，无需再提交公司董事会或 ...

Group 1 - The core viewpoint of the news highlights the recent performance and financial metrics of Changshan Pharmaceutical, including stock price movements and trading volumes [1][2] - On September 2, Changshan Pharmaceutical's stock fell by 4.27%, with a trading volume of 1.565 billion yuan. The net financing purchase on that day was 15.3582 million yuan, with a total financing and securities balance of 1.985 billion yuan [1] - The financing balance of Changshan Pharmaceutical accounts for 4.44% of its circulating market value, indicating a high level compared to the past year [1] Group 2 - As of August 29, the number of shareholders of Changshan Pharmaceutical decreased to 49,500, while the average circulating shares per person increased by 6.61% to 18,525 shares [2] - For the first half of 2025, Changshan Pharmaceutical reported an operating income of 492 million yuan, a year-on-year decrease of 13.42%, and a net profit attributable to shareholders of -29.089 million yuan, which represents a year-on-year increase of 37.98% [2] - The company has distributed a total of 181 million yuan in dividends since its A-share listing, with 4.5953 million yuan distributed over the past three years [2]

Core Viewpoint - Changshan Pharmaceutical (300255) reported that as of August 29, the number of its shareholders reached 49,537 [1] Summary by Relevant Categories - Company Information - As of August 29, Changshan Pharmaceutical had a total of 49,537 shareholders [1]

Group 1 - The number of shareholders for Changshan Pharmaceutical as of August 31 is 49,537, a decrease of 3,275 from the previous period, representing a decline of 6.20% [2] - The stock price of Changshan Pharmaceutical closed at 50.85 yuan, an increase of 0.85%, with a cumulative increase of 5.76% since the concentration of chips began [2] - The latest margin trading data shows that the total margin balance as of August 29 is 1.915 billion yuan, with an increase of 56.08 million yuan, or 3.02%, since the concentration of chips began [2] Group 2 - The company's semi-annual report indicates that it achieved operating revenue of 492 million yuan in the first half of the year, a year-on-year decrease of 13.42% [2] - The net profit for the same period is -29.089 million yuan, an increase of 37.98% year-on-year, with basic earnings per share at -0.0300 yuan [2]

Group 1 - The chemical pharmaceutical sector increased by 2.53% on August 25, with Shutaishen leading the gains [1] - The Shanghai Composite Index closed at 3883.56, up 1.51%, while the Shenzhen Component Index closed at 12441.07, up 2.26% [1] - Notable gainers in the chemical pharmaceutical sector included: - Buzoushen (300204) with a closing price of 61.00, up 16.17% and a trading volume of 445,500 shares [1] - Haichen Pharmaceutical (300584) with a closing price of 58.95, up 13.61% and a trading volume of 217,200 shares [1] - Changshan Pharmaceutical (300255) with a closing price of 53.25, up 12.84% and a trading volume of 683,900 shares [1] Group 2 - The chemical pharmaceutical sector experienced a net outflow of 426 million yuan from institutional investors, while retail investors saw a net inflow of 509 million yuan [2] - The top stocks by net inflow from retail investors included: - Anglikang (002940) with a net inflow of 163 million yuan, representing 22.87% of its trading volume [3] - Haichen Pharmaceutical (300584) with a net inflow of 132 million yuan, representing 10.90% of its trading volume [3] - Lingkang Pharmaceutical (603669) with a net inflow of 64.68 million yuan, representing 37.53% of its trading volume [3]

天眼查商业履历信息显示，河北常山生化药业股份有限公司，成立于2000年，位于石家庄市，是一家以 从事医药制造业为主的企业。企业注册资本91906.0878万人民币，实缴资本51858万人民币。公司法定 代表人为高晓东。 通过天眼查大数据分析，河北常山生化药业股份有限公司共对外投资了11家企业，参与招投标项目756 次，知识产权方面有商标信息22条，专利信息51条，此外企业还拥有行政许可95个。 资金流向方面，今日主力资金净流入2.32亿元，占比成交额6.59%。其中，超大单净流入2.58亿元、占 成交额7.32%，大单净流出2565.64万元、占成交额0.73%，中单净流出流出24864.43万元、占成交额 7.05%，小单净流入1636.04万元、占成交额0.46%。 常山药业最新一期业绩显示，截至2025中报，公司营业总收入4.92亿元、同比减少13.42%，归属净利润 2908.90万元，同比增长37.98%，扣非净利润3025.89万元，同比增长43.62%，流动比率0.791、速动比率 0.289、资产负债率66.97%。 金融界消息 截至2025年8月25日收盘，常山药业（300255）报收于53 ...

Group 1 - Company Kexing Pharmaceutical is planning to issue H-shares and list on the Hong Kong Stock Exchange, with discussions ongoing with relevant intermediaries, but specific details are yet to be determined [1] - In the first half of 2025, Kexing Pharmaceutical reported revenue of 700 million yuan, a year-on-year decrease of nearly 8%, while net profit attributable to shareholders increased by 576% to 80.34 million yuan [1] Group 2 - Company Junshi Biosciences has completed the administration of the first patient in the U.S. for the international multi-center Phase II clinical study of HLX43, a PD-L1 antibody-drug conjugate for advanced non-small cell lung cancer [2] - The clinical study is also being conducted in China, with plans to expand to Australia and Japan when conditions permit [2] Group 3 - Company Sanofi Biologics announced that shareholders plan to reduce their holdings by a total of up to 3.43%, with specific reductions from various executives and shareholders scheduled between September 15 and December 14, 2025 [3] - This potential reduction may cause short-term fluctuations in the stock price, while the long-term value will depend on the company's core business developments [3] Group 4 - Company Changshan Pharmaceutical reported a net loss of approximately 29.09 million yuan for the first half of 2025, with revenue of about 492 million yuan, a year-on-year decrease of 13.42% [4] - The company needs to focus on business restructuring and improving product competitiveness to enhance performance and profitability [4] Group 5 - Company Tianyao Pharmaceutical reported a revenue of approximately 1.588 billion yuan for the first half of 2025, a year-on-year decrease of 11.81%, with a net profit of about 49.3 million yuan, down 65.28% [5] - The decline in revenue and net profit is attributed to price reductions from centralized procurement and market competition affecting raw materials, alongside a fine exceeding 69 million yuan due to monopoly issues [5]

Core Viewpoint - The financial performance of Changshan Pharmaceutical (300255) for the first half of 2025 shows a decline in revenue and an increase in net loss, indicating financial stress and operational challenges [1][3]. Financial Performance Summary - Total revenue for the first half of 2025 was 492 million yuan, a decrease of 13.42% compared to the same period in 2024 [1]. - The net profit attributable to shareholders was -29.09 million yuan, an improvement of 37.98% year-on-year [1]. - The gross margin was 14.54%, down 8.28% year-on-year, while the net margin was -7.37%, an increase of 10.82% [1]. - The total of selling, administrative, and financial expenses was 104 million yuan, accounting for 21.19% of revenue, a decrease of 12.23% year-on-year [1]. - The current ratio was 0.79, indicating increased short-term debt pressure [1]. Key Financial Metrics - Cash and cash equivalents decreased by 35.71% to 218 million yuan [3]. - Accounts receivable increased by 10.89% to 332 million yuan [3]. - Interest-bearing liabilities rose by 2.95% to 2.461 billion yuan [3]. - Earnings per share improved to -0.03 yuan, a 40% increase year-on-year [1]. Operational Insights - The decline in revenue was attributed to decreased sales of heparin raw materials and low molecular weight heparin preparations [3]. - Significant changes in financial items included a 30.92% increase in accounts receivable and a 26.21% increase in short-term borrowings [3]. - The company experienced a 65.43% reduction in selling expenses due to changes in marketing strategies [3]. Cash Flow and Debt Analysis - The net cash flow from operating activities decreased by 13.95%, primarily due to reduced cash receipts from sales [3]. - The company’s cash flow situation is concerning, with cash and cash equivalents only covering 10.07% of current liabilities [5]. - The interest-bearing debt ratio reached 53.42%, indicating a high level of leverage [5]. Historical Performance Context - The company's historical return on invested capital (ROIC) has been weak, with a median of 7.03% over the past decade and a particularly poor ROIC of -23.95% in 2023 [4]. - The company has reported losses in two of the last ten years, reflecting a fragile business model [4].

Core Insights - The company has shown initial success in its strategic transformation, with a significant reduction in sales and management expenses leading to a narrowing of net profit loss by 37.98% year-on-year [1][2] Financial Performance - The company reported operating revenue of 492 million yuan, with a net profit attributable to shareholders of -29.09 million yuan, a year-on-year improvement of 37.98% [2] - The net cash flow from operating activities reached 173 million yuan, demonstrating strong cash collection capabilities despite a slight year-on-year decline of 13.95% [2] - The debt structure has improved, with a stable debt-to-asset ratio of 67% and long-term loans reduced to 4.358 billion yuan [2] Innovation Pipeline - The core product, Aibennate, has made significant progress in diabetes and weight loss indications, with its New Drug Application (NDA) for diabetes already accepted by the National Medical Products Administration [3] - Aibennate is expected to enter the market soon, targeting a global market exceeding 100 billion USD for weight loss drugs by 2030 [3] - The company is also advancing its second key product, CSCJC3456, an FGFR inhibitor, which is currently in Phase I clinical trials for advanced malignant tumors [3][4] Cost Management and International Expansion - The company has achieved cost reductions in its heparin business, with a self-supply rate of 65% for heparin crude products, leading to a 12% reduction in per-ton costs compared to external purchases [5] - The export revenue from heparin sodium injection has increased by 21% year-on-year, supported by registrations in countries like Tanzania and Belarus [5] - The company has established multiple national and provincial research platforms, with a total of 108 invention patents, enhancing its innovation and international competitiveness in the biopharmaceutical sector [5]

智通财经APP讯，常山药业(300255.SZ)发布2025年半年度报告，该公司营业收入为4.92亿元，同比减少 13.42%。归属于上市公司股东的净亏损为2908.9万元，同比收窄37.98%。归属于上市公司股东的扣除非 经常性损益的净亏损为3025.89万元，同比收窄43.62%。基本每股亏损为0.03元。 ...